Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: A gynecologic oncology group study

Journal of Clinical Oncology

Volumn 19, Issue 12, 2001, Pages 2975-2982

  Fracasso, P M ^a   Brady, M F ^a   Moore, D H ^a   Walker, J L ^a   Rose, P G ^a   Letvak, L ^a   Grogan, T M ^a   McGuire, W P ^a  

^a GOG Administrative Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; PACLITAXEL; VALSPODAR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CEREBELLAR ATAXIA; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0035876393     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.12.2975     Document Type: Article

References (32)

1. Cancer statistics, 2001
2. The treatment of epithelial ovarian cancer
3. Biochemistry of multidrug resistance mediated by the multidrug transporter
4. Multidrug resistance in human cancer
5. P-glycoprotein-mediated multidrug resistance: Experimental and clinical strategies for its reversal
6. SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug resistance modifier
7. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative
8. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin
9. SDZ PSC 833, a non-immunosuppressive cyclosporine: Its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia
10. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833
11. Restoration of Taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446
12. Phase I trial of paclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator
13. Phase I trial of paclitaxel (Taxol) and SDZ PSC 833 in patients with solid tumors
14. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
15. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies
16. Kinetic-mode, automated double-labeled immunohistochemistry and in situ hybridization in diagnostic pathology
17. Optimal two-stage designs for phase II clinical trials
18. Confidence limits for probability of response in multistage phase II clinical trials
19. Nonparametric estimation from incomplete observations
20. Phase I study of paclitaxel in combination with a multidrug resistance modulator. PSC 833 (valspodar), in refractory malignancies
21. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
22. SDZ PSC 833/paclitaxel in paclitaxel refractory ovarian carcinoma: A phase II trial with renewed responses
23. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer
24. Mechanisms of drug resistance in ovarian cancer
25. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma
26. MDRI and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors
27. Multidrug resistance
28. Clinical reversal of drug resistance in ovarian cancer
29. Overcoming drug resistance in ovarian carcinoma
30. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833
31. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance